

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1a of Section IV to GF/B35/ER07 ("Table 1a");
2. Approves the reinvestment of within-allocation efficiencies for the Iran HIV grant and its resultant total program budget, as listed in Table 1b of Section IV to GF/B35/ER07;
3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
4. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;
5. Approves the additional incremental funding and implementation period recommended for (a) Ghana malaria, (b) Mozambique HIV, (c) Tanzania HIV and (d) Uganda malaria disease components, and each component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;
6. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;
7. Approves the additional incremental funding and implementation period recommended for Zimbabwe HIV disease component, being an Early Applicant grant, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;
8. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and

9. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1a: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation

N	Applicant	Disease component	Proposed Principal Recipient (Grant Name)	Grant End Date	Currency	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
							Existing Funding	Recommended Incremental Funding				
1	Angola	TB/HIV	AGO-H-UNDP	30 June 2018	US\$	30,002,727	1,320,130	28,682,597	28,682,597	3,876,506	39,496,587	60 million
2		Malaria	AGO-M-MOH	30 June 2018	US\$	38,833,100	12,539,832	18,090,175	26,293,268	0	0	52.4 million
			AGO-M-WVI ¹	30 June 2018			0	8,203,093			0	
3	Central African Republic	Malaria	CAF-M-IFRC	31 December 2017	€	17,961,025	7,369,631	10,591,394	10,591,394	2,106,420	0	n/a
4	Haiti	HSS	HTI-C-PSI	31 December 2017	US\$	65,248,708	61,123,404	4,125,304	4,125,304	1,183,667	0	669 million
5	Honduras	HIV	HND-H-CHF	31 July 2019	US\$	15,205,042	2,194,093	13,010,949	13,010,949	0	n/a	79.5 million

¹ The Angola Malaria AGO-M-WVI grant includes one module originally proposed within the Angola HSS concept note (Community Workforce module for US\$2,751,590). The remaining Angola HSS grant will be presented for GAC review at a subsequent meeting.

6	Kosovo	HIV/AIDS	KOS-711-Go4-H	31 December 2017	€	1,493,276	146,092	1,347,184	1,347,184	n/a	0	1.67 million
7	Liberia	Malaria	LBR-M-MOH	30 June 2018	US\$	39,766,427	21,909,262	5,689,575	14,703,040	7,330,340	3,009,691	6 million
			LBR-M-PII	30 June 2018			3,154,125	9,013,465				
8	Madagascar	Malaria	MDG-M-PSI	30 June 2018	US\$	59,611,390	39,731,456	1,000,000	1,000,000	0	0	16.7 million
			MDG-M-MOH	30 June 2018			18,879,934	0				
9	Mauritania	TB	MRT-T-SECNLS	31 December 2018	US\$	4,838,927	0	4,838,927	4,838,927	0	0	3 million
10		HIV/AIDS	MRT-H-SECNLS	31 December 2018	US\$	9,223,633	1,651,296	7,572,337	7,572,337	0	0	4 million
11		Malaria	MRT-M-SECNLS	31 December 2018	US\$	15,554,200	0	15,554,200	15,554,200	0	0	7 million
12	Namibia ²	TB	NMB-T-MoHSS	31 December 2017	US\$	15,289,132	15,289,132	0	0	n/a	0	62.5 million
13	Peru	HIV/AIDS	PER-H-PATH	30 June 2019	US\$	12,487,092	5,924,380	6,562,712	6,562,712	0	410,477	213.9 million

² The Namibia malaria grant is a simplified application with no material reprogramming.

14	Sierra Leone	Malaria	SLE-Z-MOHS	30 June 2018	US\$	36,049,992	14,671,597	16,046,587	16,046,587	2,829,478	2,436,645	3.5 million
			SLE-M-CRSSL	30 June 2018			5,331,808	0				

Table 1b: Reinvestment of Within-Allocation Efficiencies for Previously-Approved Programs

N	Applicant	Disease Component	Grant Name	Currency	Period of Extension (Months)	Previously Approved Grant Budget	Revised Budget for Board Approval	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Iran	HIV/AIDS	IRN-H-UNDP	US\$	n/a	11,961,295	13,131,823	3,035,807	1,170,528	8,925,488	0	0	n/a

Table 2: Secretariat's Recommendation on Shortened Grants and Early Applicants

N	Applicant	Disease Component	Grant Name	Currency	Period of Extension (Months)	Previously Approved Grant Budget	Revised Budget for Board Approval	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Ghana	Malaria	GHA-M-AGAMAL	US\$	12	13,325,139	23,060,609 ³	13,325,139	4,454,139	0	0	0	0
2	Mozambique	HIV/AIDS	MOZ-H-MOH	US\$	12	180,928,522	280,497,506	128,925,773	155,886	52,002,749	76,981,737	76,981,737	143,886,779
3	Tanzania	HIV/AIDS	TZA-H-MOF	US\$	12	277,193,628	423,842,884 ⁴	104,745,414	0	172,448,214	109,078,557	109,078,557	307,125,310

³ The revised budget reflects reinvestment of cash balance of US\$4,454,139 from closed Round 8 malaria grant GHN-809-Go8-M and transfer of US\$5,281,331 from GHA-M-MOH.

⁴ Represents scenario 1 proposed by the Country Team for GAC endorsement to scale up ART with additional reinvestment of efficiencies. The revised budget reflects the original approved budget amount of US\$277,193,628, the revised signed budget amount of US\$277,593,629 due to special initiative funding, and the additional incremental funding of US\$109,078,557 recommended by the GAC for Board approval.

4	Uganda	Malaria	UGA-M-MoFPE D	US\$	12	121,346,277	145,743,990	13,422,506	0	107,923,77 1	24,398,252	39,383,30 4	41,124,714
			UGA-M-TAS O		12	30,431,393	44,606,581	2,201,263	0	28,230,130	14,985,052		
6	Zimbabwe	HIV/AIDS	ZIM-H-UNDP	US\$	12	468,705,052	611,375,034	311,217,127	0	126,053,78 2	142,669,982	142,669,98 2	127,621,03 6